CoChat

α‐particle therapy for synovial sarcoma in the mouse using an astatine‐211‐labeled antibody against frizzled homolog 10

Open access
Li, Huizi Keiko, Sugyo, Aya, Tsuji, Atsushi B., Morokoshi, Yukie, Minegishi, Katsuyuki, Nagatsu, Kotaro, Kanda, Hiroaki, Harada, Yosuke, Nagayama, Satoshi, Katagiri, Toyomasa, Nakamura, Yusuke, Higashi, Tatsuya, Hasegawa, Sumitaka · 2018 · Cancer Science
Cited by 41

The DOI matches its Crossref record.

Abstract

Synovial sarcoma (SS) is a rare yet refractory soft‐tissue sarcoma that predominantly affects young adults. We show in a mouse model that radioimmunotherapy (RIT) with an α‐particle emitting anti‐Frizzled homolog 10 (FZD 10) antibody, synthesized using the α‐emitter radionuclide astatine‐211 (211 At‐OTSA 101), suppresses the growth of SS xenografts more efficiently than the corresponding β‐particle emitting anti‐FZD 10 antibody conjugated with the β‐emitter yettrium‐90 (90 Y‐OTSA 101). In biodistribution analysis, 211 At was increased in the SS xenografts but decreased in other tissues up to 1 day after injection as time proceeded, albeit with a relatively higher uptake in the stomach. Single 211 At‐OTSA 101 doses of 25 and 50 μCi significantly suppressed SS tumor growth in vivo, whereas a 50‐μCi dose of 90 Y‐OTSA 101 was needed to achieve this. Importantly, 50 μCi of 211 At‐OTSA 101 suppressed tumor growth immediately after injection, whereas this effect required several days in the case of 90 Y‐OTSA 101. Both radiolabeled antibodies at the 50‐μCi dosage level significantly prolonged survival. Histopathologically, severe cellular damage accompanied by massive cell death was evident in the SS xenografts at even 1 day after the 211 At‐OTSA 101 injection, but these effects were relatively milder with 90 Y‐OTSA 101 at the same timepoint, even though the absorbed doses were comparable (3.3 and 3.0 Gy, respectively). We conclude that α‐particle RIT with 211 At‐OTSA 101 is a potential new therapeutic option for SS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cas.13636

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

Metadata

Authors
Li, H. K., Sugyo, A., Tsuji, A. B., Morokoshi, Y., Minegishi, K., Nagatsu, K., Kanda, H., Harada, Y., Nagayama, S., Katagiri, T., Nakamura, Y., Higashi, T., & Hasegawa, S.
Venue
Cancer Science
Publisher
Wiley
Published
2018-06-27
Volume
109
Issue
7
Pages
2302-2309
ISSN
  • 1347-9032 (ISSN-L)
  • 1349-7006
OpenAlex
W2810888503
Cited by
41
References
0
FWCI
3.94
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.